Podcast Q&A: An Introduction to Infectious Disease Modeling
This podcast segment from ICON's September 29, 2022 webinar features the Q&A with Marija Zivkovic-Gojovic, Richard Pitman, and Pragya Khurana [...]
AbbVie HEOR Expert Notes Lack of Diversity Negatively Impacts Clinical Trials, RWD Offers Possible Solution
Vice President and Global Head of Health Economics and Outcomes Research (HEOR) at AbbVie Dr. Chris Boone notes that the [...]
How to Develop the Right Drugs and How to Pay for Them
Tune in to this health care podcast with drug affordability expert Dr. Bruce Rector as he discusses how to leverage [...]
Incentivizing Novel Antibiotic Development–Netflix-Style
Drug makers have been increasingly disincentivized from developing novel antibiotics due to higher development costs and antibiotic stewardship programs, resulting [...]
Payer Contact in a “Contactless” World: Achieving Early Engagement
The COVID-19 pandemic has prompted life sciences organizations to quickly pivot their payer strategic approach and tactical implementation. Engaging payers [...]
Payer Contact in a “Contactless” World: Achieving Early Engagement
In the first of a two-part series on early engagement with payers, Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Allen Lising, Managing Director of FormularyDecisions at Xcenda to discusss this innovative platform.
OptumRx’s Calabrese: Top 3 Drugs in Pipeline
OptumRx Senior Vice President and Chief Pharmacy Officer David Calabrese in a recent interview with Managed Healthcare Executive discusses the [...]
Analysis Finds Clinical Trial Costs are Actually Modest
A new analysis published in BMJ Open suggests that clinical trial costs for new drugs are generally modest, according to [...]
Antonijevic Talks Adaptive Design Methods in Free On-Demand Webinar
Zoran Antonijevic, chair and leader of the DIA Adaptive Design Scientific Working Group, in an interview with Cytel discussed adaptive [...]
MSK’s Bach Talks High-Value Drug Development
Memorial Sloan Kettering Cancer Center's Dr. Peter Bach in a recent interview with Liam Bendicksen discusses ways to optimize high-value [...]
Report Shows Drug Development Costs Less than What Companies Say
While the pharmaceutical industry cites a $2.8 billion figure for the price of developing a new drug, a team of [...]
Tackling Rare Diseases with an Arsenal of Real-World Data
Technological innovations have fostered the age of big data in healthcare – and the huge populations amassed afford the ability to mine for key subpopulations -- getting down to ever more precise groups of likely responders to therapy, high-risk patients and other high-value subphenotypes.
Analysis Looks at ICER’s FDA Outreach Plan
A recent analysis by the Pink Sheet spotlights a new initiative by the Institute for Clinical and Economic Review (ICER) [...]
